



The HTA Trends of Recently Approved Gene Therapies Across EU4, U.S & England

———— SUPPLEMENTARY MATERIAL ————

Abbreviation list:

- **AADC:** Aromatic L-amino acid decarboxylase
- **AEMPS** Spanish HTA body (Española de Medicamentos y Productos Sanitarios)
- **ASMR:** Added Therapeutic Benefit (Amélioration du service médical rendu)
- **AIFA:** Italian HTA body (Agenzia Italiana del Farmaco)
- **BI:** Budget Impact
- **CE:** Cost-Effectiveness
- **EJ:** Early Juvenile
- **G-BA:** German HTA body (Gemeinsamer Bundesausschuss)
- **HAS:** French HTA body (Haute Autorité de Santé)
- **HTA:** Health Technology Assessment:
- **ICER:** Institute for Clinical and Economic Review
- **ITC:** Indirect Trial Comparison
- **MLD:** Metachromatic Leukodystrophy
- **NICE:** National Institute for Health and Care Excellence
- **OBA:** Outcomes-based agreement
- **PRO:** Patient-Reported Outcomes

- **QoL:** Quality of Life
- **RCT:** Randomized Controlled Trial
- **RWE:** Real-world evidence
- **SoC:** Standard of Care
- **TC:** Transparency Committee

Reference list:

Zolgensma:

1. ICER (2019) Spinraza and Zolgensma for Spinal Muscular Atrophy: Effectiveness and Value Final Evidence Report [Online]. Available at https://icer.org/wp-content/uploads/2020/10/ICER_SMA_Final_Evidence_Report_110220.pdf
2. APM (2019) ICER says U.S. pricing levels for Spinraza and Zolgensma too high, AveXis calls 'final' assessment flawed [Online]. Available at <https://www.apmhealthurope.com/story/19547/63452/icer-says-u-s-pricing-levels-for-spinraza-and-zolgensma-too-high%2C-avexis-calls-%E2%80%98final%E2%80%99-assessment-flawed>
3. G-BA (2021) Justification of Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive: Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V Onasemnogene abeparvovec (exceeding € 50 million turnover limit: Spinal muscular atrophy [Online]. Available at https://www.g-ba.de/downloads/40-1465-8006/2021-11-04_AM-RL-XII_Onasemnogen-Abeparvovec_D-679_TrG_EN.pdf
4. HAS (2023) ZOLGENSMA (onasemnogen abeparvovec) - Spinal muscular atrophy [Online]. Available at https://www.has-sante.fr/jcms/p_3442932/en/zolgensma-onasemnogene-abeparvovec-amyotrophie-spinale
5. APM (2021) French cost-effectiveness body highlights numerous uncertainties and 'extremely high' cost/result report for Novartis Zolgensma for SMA [Online]. Available at <https://www.apmhealthurope.com/story/19547/73301/french-cost-effectiveness-body-highlights-numerous-uncertainties-and--extremely-high--cost-result-report-for-novartis-zolgensma-for-sma>
6. APM (2021) Italy reimburses Novartis' Zolgensma for SMA1 in children weighing under 13.5 kg [Online]. Available at <https://www.apmhealthurope.com/story/19547/73183/italy-reimburses-novartis--zolgensma-for-sma1-in-children-weighing-under-13-5-kg>
7. APM (2021) Italy prices Novartis' gene therapy Zolgensma at €2.1 million in 'payment at result' reimbursement contract [Online]. Available at <https://www.apmhealthurope.com/story/19547/73270/italy-prices-novartis--gene-therapy-zolgensma-at-e2-1-million-in--payment-at-result-reimbursement-contract>
8. APM (2021) Italy rates Novartis' Zolgensma as innovative in SMA 1 after comparison with Biogen's Spinraza [Online]. Available at <https://www.apmhealthurope.com/story/19547/74301/italy-rates-novartis--zolgensma-as-innovative-in-sma-1-after-comparison-with-biogen-s-spinraza>

9. GAZZETTA UFFICIALE (2021) Determination of Reimbursement scheme and price of medicinal products for human use 'Zolgensma'. [Online]. Available at <https://www.gazzettaufficiale.it/eli/id/2021/03/13/21A01554/sg>
10. AEMPS (2022) IPT Report Zolgensma [Online]. Available at https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/2022/IPT_11-2022-Zolgensma.pdf
11. NICE (2023) Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy; Highly Specialised Technologies Guidance [Online]. Available at <https://www.nice.org.uk/guidance/hst24/chapter/1-Recommendations>

Libmeldy

1. ICER (2023) Atidarsagene autotemcel for metachromatic leukodystrophy: Draft evidence report [Online]. Available at https://icer.org/wp-content/uploads/2023/03/ICER_MLD-Draft-Report_For-Publication_07262023.pdf
2. G-BA (2021) Benefit assessment procedure for [the active substance atidarsagene autotemcel OTL-200 \(Metachromatic leukodystrophy with biallelic mutation in the ARSA gene\)](#) [Online]. Available at <https://www.g-ba.de/beschluesse/5103/>
3. HAS (2022) Libmeldy [Online]. Available at https://www.has-sante.fr/jcms/p_3263782/fr/libmeldy-2-10-x-106-cellules/ml-dispersion-pour-perfusion-atidarsagene-autotemcel
4. GAZZETTA UFFICIALE (2021) Reclassification of the medicinal product for human use 'Libmeldy' [Online]. Available at <https://www.gazzettaufficiale.it/eli/id/2022/04/07/22A02124/SG>
5. Orchard Therapeutics (2022) Press release: Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy [Online]. Available at: <https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-announces-reimbursement-agreement-making>
6. NICE (2022) Atidarsagene autotemcel for treating metachromatic leukodystrophy; highly specialised technologies guidance [Online]. Available at <https://www.nice.org.uk/guidance/hst18/chapter/1-Recommendations>

Zynteglo

1. ICER (2022) Betibeglogene Autotemcel for Beta Thalassemia: Effectiveness and Value; final evidence report ([Online]. Available at https://icer.org/wp-content/uploads/2021/11/ICER_Beta-Thalassemia_Final-Report_071922.pdf

2. G-BA (2020) benefit assessment [Online]. Available at https://www.g-ba.de/downloads/40-1465-6567/2020-05-14_AM-RL-XII_Betibeglogene-autotemcel_D-497_TrG_EN.pdf
3. HAS (2020) Zynteglo [Online]. Available at [High Authority of Health - ZYNTGLO \(betibéglogène autotemcel\) \(has-sante.fr\)](https://www.has-sante.fr/en/medicines/zyn-teglo)
4. NICE (2021) Appraisal consultation document Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [Online]. Available at <https://www.nice.org.uk/guidance/gid-ta10334/documents/129>

Upstaza

1. HAS (2023) Upstaza [Online]. Available at https://www.has-sante.fr/jcms/p_3398542/en/upstaza-eladocagene-exuparvoveC
2. G-BA (2023) Benefit assessment Eladocagene Exuparvovec [Online]. Available at https://www.g-ba.de/downloads/40-268-9247/2023-02-02_AM-RL-XII_Eladocagene%20Exuparvovec_D-856_TrG.pdf
3. APM (2023) Germany's G-BA rates PTC's gene therapy Upstaza with 'unquantifiable added benefit' in rare disease AADC [Online]. Available at <https://www.apmhealthurope.com/story/19813/82949/germany-s-g-ba-rates-ptc-s-gene-therapy-upstaza-with--unquantifiable-added-benefit--in-rare-disease-aadc>
4. NICE (2023) Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [Online]. Available at <https://www.nice.org.uk/guidance/gid-hst10052/documents/final-evaluation-determination-document>
5. APM (2023) NICE backs routine reimbursement of PTC's Upstaza gene therapy for rare genetic disorder [Online] Available at: <https://www.apmhealthurope.com/story/19813/83627/nice-backs-routine-reimbursement-of-ptc-s-upstaza-gene-therapy-for-rare-genetic-disorder>

Luxturna

1. ICER (2018) Voretigene Neparvovec for Biallelic RPE65- Mediated Retinal Disease: Effectiveness and Value Final Evidence Report [Online]. Available at https://icer.org/wp-content/uploads/2020/10/MWCEPAC_VORETIGENE_FINAL_EVIDENCE_REPORT_02142018.pdf
2. G-BA [2019] Benefit Assessment Voretigene Neparvovec [Online]. Available at: https://www.g-ba.de/downloads/40-1465-6053/2019-10-17_AM-RL-XII_Voretigen%20Neparvovec_D-436_TrG_EN.pdf

3. AIFA (2020) [Online]. Available at https://www.aifa.gov.it/documents/20142/961234/Determina_DG-1344-2020_Luxturna.pdf
4. AEMPS (2021) IPT report Voretigene Neparvovec [Online]. Available at https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/2021/IPT_29-2021-Luxturna.pdf
5. NICE [2019] Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations; highly specialised technologies guidance [Online]. Available at <https://www.nice.org.uk/guidance/hst11/resources/voretigene-neparvovec-for-treating-inherited-retinal-dystrophies-caused-by-rpe65-gene-mutations-pdf-50216253809605>

Hemgenix

1. APM (2023) [Online] Available at: [APM](https://www.apmhealthurope.com/story/20300/84263/germany-s-q-ba-sets-framework-for-rwe-collection-on-csl-s-gene-therapy-hemgenix-haemophilia-b)
<https://www.apmhealthurope.com/story/20300/84263/germany-s-q-ba-sets-framework-for-rwe-collection-on-csl-s-gene-therapy-hemgenix-haemophilia-b>
2. APM (2023) [Online] Available at: [APM Health Europe - CSL Behring launches haemophilia B gene therapy Hemgenix in Germany, proposes annual rate payment model](#)

Roctavian

1. APM (2023) Germany's IQWiG recommends a three-year RWD collection on BioMarin's haemophilia gene therapy Roctavian [Online] Available at: <https://www.apmhealthurope.com/story/19813/83002/germany-s-iqwig-recommends-a-three-year-rwd-collection-on-biomarin-s-haemophilia-gene-therapy-roctavian>
2. Fierce Pharma (2023) BioMarin's hemophilia gene therapy may have a chance at winning over Europe: analyst [Online] Available at: [BioMarin's hemophilia gene therapy may have a chance at winning over Europe: analysts | Fierce Pharma](#)